Prostate Brachytherapy Toxicity Outcomes

7 modules

ABS Learning

08 Nov 2022




Brachytherapy refers to radiation treatment where radioactive material is placed adjacent to or directly into the tumor tissue. This is a surgical procedure usually performed by clinicians in the radiation oncology field, and it requires additional training and expertise. Many tumor sites are treated with brachytherapy, including gynecologic cancer, gastrointestinal cancer, breast cancer, ocular melanoma, sarcoma, penile cancer, as well as prostate cancer. Unlike in Europe and Canada, the utilization of brachytherapy in the United States has decreased in recent years. The reasons for this may include the development of new technologies that do not require procedural expertise (e.g., stereotactic body radiation therapy, or SBRT), nor the same level of training. In addition, remuneration changes have played a significant role in disincentivizing brachytherapy use in the US.


The American Brachytherapy Society argues that brachytherapy is the most effective form of radiation treatment for prostate cancer. In this series, we include presentations from the leading experts in the field of brachytherapy in order to discuss long-term disease outcomes, toxicity, socioeconomic issues related to the use of brachytherapy, training, and new developments in the field.


  1. Martin T. King, MD, PhD, Dana Farber Cancer Institute
  2. Mira Keyes, MD, FRCPC, British Columbia Cancer Agency (BCCA)
  3. Mitchell R. Kamrava, MD, Radiation Oncology - Cedars-Sinai Medical Center
  4. Juanita M. Crook, MD, FRCPC, University of British Columbia
  5. Gerard Morton, MD, Odette Cancer Centre / Sunnybrook Health Sciences Centre
  6. Manuj Agarwal, MD, Radiation Oncology, Penn Medicine


Learning objective: After completing Module 2: Toxicity Outcomes with Prostate Brachytherapy, the audience will have gained knowledge of long-term toxicity outcomes with prostate brachytherapy; in particular, what causes severe recital toxicity, rete of sexual preservation rate, how to reduce toxicity with HDR brachytherapy, and the role of hydrogel rectal spacers with Brachytherapy. In addition, Dr. King will review the current randomized trial in brachytherapy.

Module 1: Rectal Ulcers, Fistulas, and Brachytherapy
{{ vm.helper.t('reports.module') }}
Module 2: Quality of Life after Prostate Cancer Treatment
{{ vm.helper.t('reports.module') }}
Module 3: Sexual Function After Brachytherapy
{{ vm.helper.t('reports.module') }}
Module 4: Modern HDR Brachytherapy Techniques to Reduce Treatment Toxicity
{{ vm.helper.t('reports.module') }}
Module 5: Prostate Brachytherapy and Hydrogel Spacers
{{ vm.helper.t('reports.module') }}
Module 6: The Current State of Randomized Clinical Trial Evidence for Prostate Brachytherapy
{{ vm.helper.t('reports.module') }}
Post-Activity Survey
{{ vm.helper.t('courses.survey') }}

Shopping Cart

Your cart is empty